Senseonics Holdings (SENS) AI Stock Analysis

• Market Cap: $392.74M
• Dividend Yield: N/A
• Average Volume (3M): 6.49M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.97
• Revenue Growth: 0.37%
• EPS Growth: -20.49%
• Country: US
• Employees: 117
• Sector: Healthcare
• Sector Strength: 70
• Industry: Medical - Devices
• EPS (TTM): -0.13
• Shares Outstanding: 651,850,800
• 10 Day Avg. Volume: 3,585,608
• 30 Day Avg. Volume: 6,486,436
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 21.49
• Price to Cash Flow (P/CF): -8.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $1.70
• Price Target Upside: 183.33% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 6

Senseonics Holdings is currently facing substantial financial and operational challenges. While the launch of Eversense 365 and strategic partnerships highlight potential for future growth, the financial performance remains underwhelming with continuous losses and high leverage. Technical indicators suggest some potential for medium to long-term improvement, but valuation remains difficult given the negative earnings. The earnings call provided some optimism about strategic growth, yet persistent financial difficulties and market challenges temper this outlook.

Positive Factors

Market Growth and Adoption

Physicians expect the US CGM category to expand over 20%, surpassing the growth forecast of major competitors, indicating strong market potential.

Product Approval and Expansion

The Eversense 365 platform is the only FDA-approved implantable CGM cleared for continuous blood glucose monitoring for 12 months, offering a significant advantage over competing external platforms.

Negative Factors

Financial Concerns

SENS shares are considered expensive due to trading at a high multiple of projected sales and ongoing cash burn, increasing the risk of dilution.

Market Competition

There is skepticism about SENS's ability to gain traction in the CGM market against established competitors, despite the 365-day indication.

Senseonics Holdings Business Overview & Revenue Model

Company Description

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

How the Company Makes Money

Senseonics Holdings generates revenue primarily through the sale of its Eversense CGM system and related products. The company's revenue model involves direct sales to healthcare providers and distribution partnerships that facilitate the availability of its CGM systems in various markets. Key revenue streams include the initial purchase of the CGM system components and ongoing sales of consumables like sensors and transmitters required for continuous monitoring. Significant partnerships with healthcare providers, distribution partners, and insurers also contribute to its earnings by expanding market reach and facilitating reimbursement processes for patients.

Senseonics Holdings Financial Statement Overview

Summary

Senseonics Holdings faces significant financial challenges, including continuous losses and high leverage. While revenue shows slight growth, profitability remains a major concern with negative margins across the board. The balance sheet's negative equity and high debt levels indicate financial instability, and the cash flow statement reflects ongoing liquidity issues. The company must focus on improving operational efficiency and financial health to enhance its financial standing.

Income Statement

Senseonics Holdings has shown minimal revenue growth with a slight increase in total revenue from $22.39M in 2023 to $22.47M TTM. However, profitability metrics are concerning: Gross Profit Margin is low at 2.37%, and both EBIT and EBITDA margins are negative, indicating the company is operating at a significant loss. The Net Profit Margin is also negative, reflecting ongoing challenges in achieving profitability.

Balance Sheet

The company has a notably high Debt-to-Equity ratio due to negative equity, suggesting financial instability. The Return on Equity is not applicable due to negative equity. Additionally, the equity ratio is inverted due to negative stockholders' equity, highlighting potential financial distress. The balance sheet reveals a capital structure heavily reliant on debt.

Cash Flow

Operating cash flow remains negative, but there is a slight improvement in free cash flow from -$70.51M in 2023 to -$62.70M TTM. Operating Cash Flow to Net Income Ratio is not favorable at 0.77, indicating cash flow issues. However, financing activities have provided some cash influx, albeit this may not be sustainable long-term.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
22.47M	22.39M	16.39M	13.68M	4.95M	21.30M
	Gross Profit
533.00K	3.09M	2.73M	-811.00K	-17.37M	-19.45M
	EBIT
-74.84M	-75.60M	-68.63M	-57.18M	-79.13M	-130.66M
	EBITDA
-69.91M	-48.01M	161.81M	-284.51M	-157.86M	-99.41M
	Net Income Common Stockholders
-78.62M	-60.39M	142.12M	-317.78M	-191.02M	-126.23M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
74.60M	109.46M	144.01M	129.91M	18.00M	95.94M
	Total Assets
100.44M	138.22M	177.67M	198.93M	35.92M	132.60M
	Total Debt
60.63M	47.78M	74.65M	63.30M	62.70M	119.22M
	Net Debt
-13.97M	-27.93M	38.86M	29.84M	44.69M	23.29M
	Total Liabilities
116.99M	64.77M	180.25M	384.46M	180.00M	141.45M
	Stockholders Equity
-16.55M	73.45M	-2.58M	-185.53M	-144.08M	-8.85M
Cash Flow		Free Cash Flow
-62.70M	-70.51M	-66.62M	-56.29M	-67.60M	-137.09M
	Operating Cash Flow
-60.47M	-70.16M	-66.31M	-56.08M	-67.42M	-136.05M
	Investing Cash Flow
32.84M	89.71M	26.88M	-148.75M	-181.00K	-1.04M
	Financing Cash Flow
26.83M	20.37M	41.76M	220.08M	-10.13M	96.24M

Senseonics Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SENS, the sentiment is Negative. The current price of 0.6 is below the 20-day moving average (MA) of 0.65, below the 50-day MA of 0.79, and above the 200-day MA of 0.52, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 42.54 is Neutral, neither overbought nor oversold. The STOCH value of 34.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SENS.

Senseonics Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABT	79 Outperform	$215.92B	16.30	30.95%	1.80%	4.59%	134.50%
MDT	77 Outperform	$105.86B	25.09	8.42%	3.39%	2.72%	4.48%
PODD	76 Outperform	$18.59B	43.44	43.03%	―	22.07%	101.95%
DXCM	61 Neutral	$26.21B	47.24	27.63%	―	11.34%	4.24%
TNDM	56 Neutral	$1.13B	―	-33.30%	―	25.74%	57.18%
Sector *	48 Neutral	$6.25B	1.14	-46.26%	2.69%	19.24%	1.75%
SENS	43 Neutral	$392.74M	―	-166.29%	―	0.37%	-20.49%

Senseonics Holdings Corporate Events

Senseonics Holdings Expands with Innovative Diabetes Solutions

Senseonics Holdings, Inc. is revolutionizing diabetes management with the Eversense® 365 Continuous Glucose Monitoring (CGM) System, the only fully implantable CGM approved for a year-long duration. Recently cleared by the FDA, the Eversense® 365 addresses key complaints of comfort and accuracy, and targets the underpenetrated $20 billion U.S. CGM market. Partnering with Ascensia Diabetes Care and Mercy Health, Senseonics is poised to expand its market presence, while developing next-gen devices like the self-powering Gemini System and the Freedom System, enhancing user convenience and connectivity.